Molecular Partners’ Post

Multiple myeloma is a type of blood cancer that develops from plasma cells in a patient’s bone marrow. The ALLG has a number of active clinical trials investigating new treatments for patients with myeloma, including MM23 SEALAND. This clinical trial, led by Professor Hang Quach, is evaluating a new medicine for patients called Selinexor in the maintenance treatment phase after a stem cell transplant. MM23 is the only trial globally assessing this important new treatment option for newly diagnosed and eligible myeloma patients. Maintenance therapy is now recognised as an essential treatment strategy for prolonging progression-free survival in myeloma and potentially increasing overall survival rates for patients with this type of blood cancer. The MM23 trial is open for patient participation at 18 hospital sites across Australia and New Zealand. To learn more about MM23 and other ALLG trials for myeloma, please speak with your treating doctor or visit www.allg.org.au.  #ALLG #ALLGtrials #bettertreatmentsbetterlives #clinicaltrials   #bloodcancer #bloodcancerawareness #bloodcancercure #bloodcancers #haematology #haematologyresearch #leukaemiaandlymphoma #myeloma #myelomaawareness

We are proud to see continued strong and durable responses for our lead innate cell engager (ICE®), acimtamig (AFM13) in a patient population that is left with few options, presented at the #ASH23 Annual Meeting today. The results presented by the principal investigator Yago Nieto, M.D., Ph.D., Professor of Stem Cell Transplantation and Cellular Therapy at The University of Texas MD Anderson Cancer Center are unprecedented, especially for  patients who failed prior chemotherapy and are double-refractory to brentuximab vedotin (BV) and checkpoint inhibitors (CPIs).   Building on these results, we are well underway with our Phase 2 LuminICE-203 trial studying acimtamig in combination with AlloNK® (AB-101).  We are enrolling and dosing patients in the first two cohorts and look forward to sharing data in the first half of 2024.   We will host a webcast at 1:30 p.m. PST / 4:30 p.m. EST / 10:30 p.m. CET to review the data and provide a strategic update on acimtamig future development.    Access additional details, including dial-in information in the press release at: https://lnkd.in/dFgSRtNQ

ASH23 was made more memorable with the presenation of udpated acimtamig (AFM13) data & news on patient recruitment in our LuminICE-203 trial. Be sure to check out the details in the post below #acimtamig #AFM13

Long-term outcome after autologous BCR::ABL1-negative peripheral blood stem cell transplantation in adults with Philadelphia-positive acute lymphoblastic leukemia: a comparative study Haematologica Early view Nov 30,2023  https://lnkd.in/gs-cBSD4

We're happy to share that a poster featuring #SMART101, the first T cell progenitor therapy product in development from our ProTcell platform, will be presented at the #ASH Annual Meeting. The poster will give details of the #ReSET-02 clinical study that is underway seeking to provide proof of concept that our allogeneic T cell progenitors can rapidly complete their differentiation into naïve T cells within a patient’s #thymus, accelerating the reconstitution of a fully competent T cell repertoire after haploidentical stem cell transplantation. If the primary endpoints are met as anticipated, the study will also show the biological activity of SMART101 to reverse thymic involution. https://lnkd.in/efrgMTfn #pressrelease #ProTcell #Tcell #ASH2023 #ASH23 #ashcongress #leukemia #cancer #immunity #CGT #GMP #study #design #biotech

Today we are excited to announce our collaboration with NMDP BioTherapies to advance our TCR T-cell therapy into human trials. NMDP BioTherapies will provide healthy donor materials for our upcoming Phase 1/2a trial (TCX-101) of our first-in-human product (BSB-1001). The Phase 1/2a trial will evaluate BSB-1001 in combination with allogeneic stem cell transplant in patients with high-risk leukemias, including relapsed or refractory acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL) and myeloid dysplastic syndrome (MDS). Learn more here: https://lnkd.in/g4C5kxdy

3 Reasons why you should attend the Lymphoma, Leukemia & Myeloma Congress this October: 1. Enhancing relationships with your colleagues and meeting new peers that share the same interest 2. Gain direct access to industry experts to advance your connections and knowledge 3. Learning about new advancements and best practices in hematologic malignancies to best treat your patients. Why wait to register? Rates increase after August 2: https://lnkd.in/e2i8XbKr #llmcongress2024 #lymphoma #leukemia #myeloma #bloodcancers #oncology #education #networking #patientcare

📄 [Press release] – MaaT Pharma Announces First DSMB Positive Review of Ongoing Phase 2 Clinical Trial Evaluating MaaT033 for Patients Receiving Allo-HSCT 🩸 Key highlights: ✅ DSMB recommends proceeding as planned without modifications ✅ MaaT033 has shown to have an acceptable safety profile and was well tolerated in patients treated for blood cancers and receiving allogeneic hematopoietic stem cell transplantation (allo-HSCT). 🦠Phase 2b trial PHOEBUS, the largest one to date for a microbiome therapy in oncology, is an international, multi-center, randomized, double-blind, testing MaaT033, an oral freeze-dried formulation against placebo. https://lnkd.in/emffi3dR #Microbiome #BloodCancer #Cancer #DSMB #Safety

Post-allo-HSCT outcomes for #AML show: ▪️3-year relapse rate changed from 37%-31% and then to 30% from 2000-2021 ▪️3 year leukemia-free survival increased from 32%, 38% and, 44% ▪️OS increased from 37%, 42%, and 49% https://lnkd.in/ekejs_5d #leusm #cancer #oncology

📢Update in Follicular Lymphoma Treatment! The EBMT and ASTCT have released updated clinical guidelines for stem cell transplants in follicular lymphoma. These guidelines provide new recommendations on hematopoietic cell transplantation and cellular therapies, marking a significant advancement in treatment protocols. Key Highlights: 🔹 Autologous-HCT as an option for patients with disease progression within 24 months. 🔹 CAR-T therapy for those not achieving CR or PR after multiple lines of therapy. 🔹 Allogeneic-HCT for select relapsed chemosensitive patients post CAR-T failure. Dive into the detailed guidelines and download the PDF here: https://lnkd.in/e5N445ww Stay informed and keep up with the latest in lymphoma research! #lymsm #lymphomacoalition